• Explore /
  • Poster
  • / First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.

First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.

Abstract Poster

Authors

null

Noriko Yanagitani

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Noriko Yanagitani , Atsushi Horiike , Satoru Kitazono , Fumiyoshi Ohyanagi , Shunsuke Kondo , Akihiko Shimomura , Yutaka Fujiwara , Toshihiko Doi , Yasutoshi Kuboki , Akihito Kawazoe , Kohei Shitara , Izumi Ohno , Udai Banerji , Raghav Sundar , Shuichi Ohkubo , Jerry M. Huang , Makoto Nishio , Noboru Yamamoto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Other Novel Agents

Clinical Trial Registration Number

NCT02965885

Citation

J Clin Oncol 35, 2017 (suppl; abstr 2546)

DOI

10.1200/JCO.2017.35.15_suppl.2546

Abstract #

2546

Poster Bd #

38

Abstract Disclosures

Similar Posters

First Author: Tomoya Yokota

First Author: Shubham Pant

First Author: Quincy S. Chu

First Author: Johanna Bendell